Recipharm, a leading global contract development and manufacturing organization (CDMO), today announced a strategic collaboration with Fusix Biotech to support the development and manufacturing of next-generation cancer immunotherapies based on innovative oncolytic virus technology.

Fusix Biotech is developing breakthrough cancer treatments using proprietary oncolytic fusion virus technology designed to combine direct tumor cell destruction with modulation of the tumor microenvironment to enhance anti-tumour immune responses.

The company’s lead candidate, FUSE102, is a chimeric oncolytic virus encoding a high affinity soluble PD-1 intended to enable immune checkpoint inhibition and strengthen anti-tumor activity. The program represents a novel approach within the rapidly evolving field of cancer immunotherapy.

Under the collaboration, Recipharm will tech transfer the FUSE102 process to support clinical development building on Recipharm’s capabilities in viral vectors and advanced biologics manufacturing. Through its collaboration with iBET, who will do the initial process development, Recipharm will manufacture the Master Virus Seed and GMP clinical material for first in-human trials.

Greg Behar, CEO of Recipharm, said: “Oncolytic viruses represent one of the most promising areas in cancer immunotherapy today. We are pleased to collaborate with Fusix Biotech to help advance this innovative platform toward the clinic. This partnership reflects Recipharm’s growing expertise in complex biologics and viral-based therapies, and our ability to support customers from process development through GMP manufacturing as they advance the next generation of oncology treatments.”

Jennifer Altomonte, CEO and CSO of Fusix Biotech, added: “Partnering with Recipharm is an important step forward for Fusix Biotech and our InFUSE platform. Recipharm’s experience in viral product development and biologics manufacturing makes them a strong partner as we advance our programmes toward the clinic.”

This collaboration further demonstrates Recipharm’s capabilities in oncology biologics, where the company supports innovators with integrated development and manufacturing services, spanning viral vectors, oncolytic viruses, nucleic acids, recombinant proteins and sterile fill and finish services. Combined with Recipharm’s analytical development, process optimisation and regulatory support, these capabilities help advance complex program from early development through commercial manufacture.

For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.co